… degrader that retards cellular proliferation and induces apoptosis in multiple cancer cell lines.
Selective STAT3 depletion was achieved over … , a BCL-XL targeting PROTAC that engages …

… In this study, we used PROTAC technology to … achieve 246 tissue-specific target degradation
by leveraging tissue-specific E3 ligases. One notable example is a BCL-XL 247 degrader …

… to a more productive and selective degrader 23,25 . Hence, … selective degradation could
be achieved using a PROTAC … anti-apoptotic drugs including BCL-XL and IAP antagonists, …

… antagonists are needed to achieve robust and sustained p53 … first-generation potent β-catenin
degrader, which exhibited … PROTAC technology, we developed a class of SP-PROTAC …

… the PROTAC technology has been widely used to degrade … -controlled PROTAC
strategy not only achieves precise protein … to achieve the desired therapeutic effect of light-controlled …

… evaluation of PROTAC-8, an AZD5438-based PROTAC, that shows selective proteasomal
… for specific interactions of PROTAC-8 with CDK2 and E3 ligase. Furthermore, we show that …

… An example was the development of BCL-XL PROTACs. BCL-XL inhibitors were not … if
the mutated oncoprotein is degraded with the use of a specific PROTAC. As mentioned before, …

… using VHL E3 ligase and a BCLXL inhibitor in 2019. PROTAC degrader (104) reported
promising results against in vitro BCL-XL-dependent leukemia and cancer cells with a DC50 …

… selected PROTAC case studies from this perspective. … targets may contribute to achieve
the desired therapeutic effect. … converted into a potent dual BCL-2/BCL-xL degrader, 753b (6, …

… cMYC PROTAC has been reported to selectively degrade cMYC … As a molecule with two
warheads, hook effect may occur to … of POI, PROTAC, and E3 ligase reaches saturation and then …